



Complete Summary

GUIDELINE TITLE

Pregnant women and novel influenza A (H1N1): considerations for clinicians.

BIBLIOGRAPHIC SOURCE(S)

Centers for Disease Control and Prevention (CDC). Pregnant women and novel influenza A (H1N1): considerations for clinicians. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2009 May 21. 4 p. [1 reference]

GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

- Novel influenza A (H1N1) virus infection
- Pregnancy
- Human immunodeficiency virus (HIV) infection

GUIDELINE CATEGORY

Prevention
Treatment

CLINICAL SPECIALTY

Allergy and Immunology
Family Practice
Infectious Diseases

Internal Medicine
Obstetrics and Gynecology
Pharmacology

INTENDED USERS

Advanced Practice Nurses
Allied Health Personnel
Clinical Laboratory Personnel
Health Care Providers
Hospitals
Physician Assistants
Physicians
Public Health Departments
Respiratory Care Practitioners

GUIDELINE OBJECTIVE(S)

- To summarize information about novel influenza A (H1N1) virus infection during pregnancy
- To provide preliminary treatment recommendations to guide novel H1N1 treatment in pregnant women

TARGET POPULATION

Pregnant women (including human immunodeficiency virus [HIV]-infected women) with confirmed, probable, or suspected novel influenza A (H1N1) virus infection

INTERVENTIONS AND PRACTICES CONSIDERED

Treatment

1. Neuraminidase inhibitors antiviral therapies
 - Oseltamivir (Tamiflu) (preferred)
 - Zanamivir (Relenza)
2. Acetaminophen to reduce fever

Note: Adamantane antiviral medications (amantadine [Symmetrel®], rimantadine [Flumadine®]) were considered but not recommended.

Prevention

1. Post-exposure chemoprophylaxis
 - Zanamivir (Relenza)
 - Oseltamivir (Tamiflu)
2. Steps to reduce the chance of being exposed to respiratory infections
 - Frequent hand washing, covering coughs, and having ill persons stay home
 - Voluntary home quarantine of ill persons
 - Facemasks and respirators

3. Breast feeding considerations
 - Initiating breastfeeding early and feeding frequently
 - Eliminating unnecessary formula supplementation

MAJOR OUTCOMES CONSIDERED

- Drug tolerability
- Drug effectiveness
- Incidence of novel influenza A (H1N1) virus infection
- Morbidity and mortality associated with novel H1N1 in pregnant women

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Note from the Centers for Disease Control and Prevention (CDC): Human immunodeficiency virus (HIV)-infected pregnant women are at risk of potentially serious disease due to influenza viruses. The CDC recommends that pregnant women, including HIV-infected pregnant women, with confirmed, probable, or suspected novel influenza A (H1N1) infection receive antiviral therapy with oseltamivir (Tamiflu).

Summary

Pregnancy raises risk for complications related to seasonal as well as pandemic influenza infections such as those caused by the novel influenza A (H1N1) virus. The CDC has recently summarized information about novel H1N1 infection during pregnancy and has issued preliminary treatment recommendations, shown below.

Twenty cases of novel H1N1 (15 confirmed and 5 probable) in pregnant women have been reported in the U.S. as of May 10, 2009. Three women were hospitalized, and one of them died. Based on available data, the CDC recommends that pregnant women with confirmed, probable, or suspected novel H1N1 infection receive antiviral therapy with oseltamivir (Tamiflu; preferred for its systemic absorption) for 5 days. Therapy should be initiated as soon as possible, even if more than 48 hours have elapsed since symptom onset. Acetaminophen should also be administered, as fevers are associated with adverse maternal and fetal outcomes. Pregnant women who have had close contact with someone who has confirmed, probable, or suspected novel H1N1 infection should receive prophylaxis with either oseltamivir or zanamivir (Relenza) for 10 days.

Both the Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend annual influenza vaccination for all pregnant women. However, because the 2008–2009 seasonal vaccine does not protect against novel H1N1, even vaccinated pregnant women with flu-like symptoms should be evaluated and treated. Although the safety and efficacy of oseltamivir during pregnancy have not been firmly established, the benefits of this antiviral drug are likely to outweigh the risks. Novel H1N1 seems to be resistant to amantadine and rimantadine, so these drugs should not be used in people with suspected novel H1N1 infection.

Clinical Presentation

Pregnant women with novel influenza A (H1N1) virus would be expected to present with typical acute respiratory illness (e.g., cough, sore throat, rhinorrhea) and fever or feverishness. Many pregnant women will go on to have a typical course of uncomplicated influenza. However, for some pregnant women, illness might progress rapidly, and might be complicated by secondary bacterial infections including pneumonia. Fetal distress associated with severe maternal illness can occur. Pregnant women who have suspected novel influenza A (H1N1) virus infection should be tested, and specimens from women who have unsubtypeable influenza A virus infections should have specimens sent to the state public health laboratory for additional testing to identify novel influenza A (H1N1).

Treatment and Chemoprophylaxis

The currently circulating novel influenza A (H1N1) virus is sensitive to the neuraminidase inhibitor antiviral medications zanamivir (Relenza®) and oseltamivir (Tamiflu®), but is resistant to the adamantane antiviral medications, amantadine (Symmetrel®) and rimantadine (Flumadine®). Pregnant women who meet current case-definitions for confirmed, probable, or suspected novel influenza A (H1N1) infection should receive empiric antiviral treatment. Pregnant women who are close contacts with persons with suspected, probable or confirmed cases of novel influenza A (H1N1) should receive chemoprophylaxis.

As is recommended for other persons who are treated, antiviral treatment with zanamivir or oseltamivir should be initiated as soon as possible after the onset of influenza symptoms, with benefits expected to be greatest if started within 48 hours of onset, based on data from studies of seasonal influenza. However, some data from studies on seasonal influenza indicate benefit for hospitalized patients even if treatment is started more than 48 hours after onset. Recommended duration of treatment is five days, and for chemoprophylaxis is 10 days. Oseltamivir and zanamivir treatment and chemoprophylaxis regimens recommended for pregnant women are the same as those recommended for adults who have seasonal influenza (see Table 1 in the original guideline document). Recommendations for use of antivirals for pregnant women might change as data on antiviral susceptibilities become available.

One of the more well-studied adverse effects of influenza is its associated hyperthermia. Studies have shown that maternal hyperthermia during the first trimester doubles the risk of neural tube defects and may be associated with other birth defects and adverse outcomes. Limited data suggest that the risk for birth

defects associated with fever might be mitigated by antipyretic medications or multivitamins that contain folic acid. Maternal fever during labor has been shown to be a risk factor for adverse neonatal and developmental outcomes, including neonatal seizures, encephalopathy, cerebral palsy, and neonatal death. Even though distinguishing the effects of the cause of fever from the hyperthermia itself is difficult, fever in pregnant women should be treated because of the risk that hyperthermia appears to pose to the fetus. Acetaminophen appears to be the best option for treatment of fever during pregnancy, although data on even this common exposure are also limited.

Pregnancy should not be considered a contraindication to oseltamivir or zanamivir use. Pregnant women might be at higher risk for severe complications from novel influenza A (H1N1), and the benefits of treatment or chemoprophylaxis with zanamivir or oseltamivir likely outweigh the theoretical risks of antiviral use. Oseltamivir and zanamivir are "Pregnancy Category C" medications, indicating that no clinical studies have been conducted to assess the safety of these medications for pregnant women. Because of the unknown effects of influenza antiviral drugs on pregnant women and their fetuses, oseltamivir or zanamivir should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus. Although a few adverse effects have been reported in pregnant women who took these medications, no relation between the use of these medications and those adverse events has been established. Because of its systemic activity, oseltamivir is preferred for treatment of pregnant women. The drug of choice for prophylaxis is less clear. Zanamivir may be preferable because of its limited systemic absorption; however, respiratory complications that may be associated with zanamivir because of its inhaled route of administration need to be considered, especially in women at risk for respiratory problems.

Other Ways to Reduce Risk for Pregnant Women

There is no vaccine available yet to prevent novel influenza A (H1N1); however, the risk for novel influenza A (H1N1) might be reduced by taking steps to reduce the chance of being exposed to respiratory infections. These actions include frequent hand washing, covering coughs, and having ill persons stay home except to seek medical care, and minimize contact with others in the household. Additional measures that can limit transmission of a new influenza strain include voluntary home quarantine of members of households with confirmed or probable novel influenza A (H1N1) cases, reduction of unnecessary social contacts, and avoidance whenever possible of crowded settings. If used correctly, facemasks and respirators may help reduce the risk of getting influenza, but they should be used along with other preventive measures, such as avoiding close contact and maintaining good hand hygiene. A respirator that fits snugly on the face can filter out small particles that can be inhaled around the edges of a facemask, but compared with a facemask it is harder to breathe through a respirator for long periods of time.

Breastfeeding Considerations

Infants who are not breastfeeding are particularly vulnerable to infection and hospitalization for severe respiratory illness. Women who deliver should be encouraged to initiate breastfeeding early and feed frequently. Ideally, babies should receive most of their nutrition from breast milk. Eliminate unnecessary

formula supplementation, so the infant can receive as much maternal antibodies as possible.

If a woman is ill, she should continue breastfeeding and increase feeding frequency. If maternal illness prevents safe feeding at the breast, but she can still pump, encourage her to do so. The risk for novel influenza A (H1N1) transmission through breast milk is unknown. However, reports of viremia with seasonal influenza infection are rare.

Expressed milk should be used for infants too ill to feed at the breast. In certain situations, infants may be able to use donor human milk from a Human Milk Banking Association of North American (HMBANA)-certified milk bank.

Antiviral medication treatment or prophylaxis is not a contraindication for breastfeeding.

Instruct parent and caretakers on how to protect their infant from the spread of germs that cause respiratory illnesses like novel influenza A (H1N1):

- Wash adults' and infants' hands frequently with soap and water, especially after infants place their hands in their mouths.
- Keep infants and mothers as close together as possible and encourage early and frequent skin-to-skin contact between mothers and their infants.
- Limit sharing of toys and other items that have been in infants' mouths. Wash thoroughly with soap and water any items that have been in infants' mouths.
- Keep pacifiers (including the pacifier ring/handle) and other items out of adults' or other infants' mouths prior to giving to the infant.
- Practice cough and sneeze etiquette.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Effective treatment of novel influenza A (H1N1) in pregnant women
- Reduced adverse pregnancy outcomes due to novel H1N1 infection

POTENTIAL HARMS

- Because of the unknown effects of influenza antiviral drugs on pregnant women and their fetuses, oseltamivir or zanamivir should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus. Although a few adverse effects have been reported in pregnant women who took these medications, no relation between the use of these medications and those adverse events has been established. Because of its systemic activity, oseltamivir is preferred for treatment of pregnant women.
- Respiratory complications that may be associated with zanamivir because of its inhaled route of administration need to be considered, especially in women at risk for respiratory problems.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Staying Healthy

IOM DOMAIN

Effectiveness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Centers for Disease Control and Prevention (CDC). Pregnant women and novel influenza A (H1N1): considerations for clinicians. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2009 May 21. 4 p. [1 reference]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2009 May 21

GUIDELINE DEVELOPER(S)

Centers for Disease Control and Prevention - Federal Government Agency [U.S.]

SOURCE(S) OF FUNDING

United States Government

GUIDELINE COMMITTEE

Not stated

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Not stated

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the [Centers for Disease Control and Prevention \(CDC\) Web site](#).

Print copies: Available from the Centers for Disease Control and Prevention, MMWR, Atlanta, GA 30333. Additional copies can be purchased from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325; (202) 783-3238.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on June 24, 2009.

COPYRIGHT STATEMENT

No copyright restrictions apply.

DISCLAIMER**NGC DISCLAIMER**

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

[Copyright/Permission Requests](#)

Date Modified: 7/27/2009

